What is BioMedomics?
Headquartered in Research Triangle Park, North Carolina, BioMedomics operates as a subsidiary of OraSure Technologies, maintaining ISO 13485 certification. The company is primarily recognized for its pioneering work in hematology and infectious disease diagnostics. Its flagship innovation, Sickle SCAN, represents a significant advancement in medical technology, providing a rapid, field-deployable solution for sickle cell disease detection. By eliminating the reliance on centralized laboratory infrastructure, BioMedomics effectively bridges the gap in diagnostic accessibility, particularly within under-resourced clinical environments. Their commitment to R&D ensures a robust pipeline of affordable, high-accuracy diagnostic tools designed to meet critical global healthcare demands.
How much funding has BioMedomics raised?
BioMedomics has raised a total of $1.2M across 2 funding rounds:
Private Equity
$690K
Private Equity
$530K
Private Equity (2013): $690K, investors not publicly disclosed
Private Equity (2017): $530K, investors not publicly disclosed
Key Investors in BioMedomics
Undisclosed Investor
An institutional capital provider focused on long-term growth and strategic development within the life sciences and medical technology sectors.
Undisclosed Investor
A private equity firm specializing in scaling healthcare infrastructure and supporting innovative diagnostic companies through late-stage financing.
Undisclosed Investor
An investment group dedicated to backing high-impact medical technology firms that address critical gaps in global diagnostic accessibility.
What's next for BioMedomics?
With the support of its recent capital injection, BioMedomics is well-positioned to accelerate its market penetration and expand its diagnostic portfolio. The strategic focus will likely center on scaling the distribution of its existing point-of-care solutions while simultaneously investing in the development of next-generation assays. As the company integrates further with OraSure Technologies, it is expected to leverage broader distribution networks to enhance its footprint in international markets. Future growth will be driven by the dual imperatives of technological innovation and the democratization of diagnostic access, ensuring that BioMedomics remains a pivotal player in the evolving landscape of global health diagnostics.
See full BioMedomics company page
